ПРОБЛЕМЫ СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ, ИНДУЦИРОВАННЫХ ХИМИОТЕРАПИЕЙ И ТАРГЕТНЫМИ ПРЕПАРАТАМИ


https://doi.org/10.17709/2409-2231-2015-2-77

Полный текст:


Аннотация

Современная лекарственная терапия существенно увеличила продолжительность жизни больных раком молочной железы, в связи с чем существенное значение приобретает ее качество. Кардиальная токсичность ряда цитостатиков может проявляться спустя годы после завершения терапии. Наиболее часто вклад в развитие кардиотоксичности вносят антрациклиновые антибиотики. Повторное их использование ограничивается суммарной дозой. Комбинация антрациклинов с трастузумабом увеличивает риск развития кардиотоксичности. Использование пегилированной липосомальной формы антрациклинов, своевременное выявление фоновых заболеваний, а также проведение профилактических мероприятий может позволить снизить риск развития этого грозного осложнения.


Об авторах

Л. В. Болотина
МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИРЦ» Минздрава России (Москва, Россия) 125284, Россия, Москва, 2-й Боткинский проезд, 3
Россия

д.м.н., заведующая отделением химиотерапии МНИОИ им. П.А.Герцена – филиала ФГБУ «НМИРЦ» Минздрава России



А. Г. Овчинников
НДО НИИ кардиологии им. А.Л.Мясникова ФГБУ РКНПК МЗ РФ , (Москва, Россия) 121552, Россия, Москва, ул. 3-я Черепковская, 15а
Россия

д.м.н., заведующий лабораторией функциональной диагностики НДО НИИ кардиологии им. А.Л.Мясникова ФГБУ РКНПК МЗ РФ



Список литературы

1. Bardia A., Arieas E. T., Zhang Z., Defilippis A., Tarpinian K., Jeter S., Nguyen A., Henry N. L., Flockhart D. A., Hayes D. F., Hayden J., Storniolo A. M., Armstrong D. K., Davidson N. E., Fetting J., Ouyang P., Wolff A. C., Blumenthal R. S., Ashen M. D., Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012; 131 (3): 907–914.

2. ESMO Guidelines Breast Cancer, 2014.

3. Perez E. A., Suman V. J., Davidson N. E., Kaufman P. A., Martino S., Dakhil S. R., Ingle J. N., Rodeheffer R. J., Gersh B. J., Jaffe A. S. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004; 22: 3700–3704.

4. Michael S. Ewer, Edward T. H. Yeh. Cancer and the Heart, Second Edition, PMPH-USA, 2013.

5. Barrett-Lee P. J., Dixon J. M., Farrell C., Jones A., Leonard R., Murray N., Palmieri C., Plummer C. J., Stanley A., Verrill M. W. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009; 20: 816–827.

6. Bryant J., Picot J., Baxter L., Levitt G., Sullivan I., Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. British Journal of cancer. 2007; 96 (2): 226–230.

7. Jensen B. V., Skovsgaard T., Nielsen S. L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, longterm observational study of outcome in 120 patients. Ann Oncol. 2002; 13: 699–709.

8. James L. Speyer, Michael D. Green, Anne Zeleniuch-Jacquotte et al. ICRF‑187 Permits Longer Treatment With Doxorubicin in Women With Breast Cancer. Journal of Clinical Oncology. 1992; 10 (1): 117–127.

9. Rowinsky E. K., Eisenhauer E. A., Chaudhry V., Arbuck S. G., Donehower R. C. Clinical toxities encountered with paclitaxel (Taxol). Semin Oncol. 1993; 4 (3); 1–15.

10. Meinardi M. T., Gietema J. A., van der Graaf W. T., van Veldhuisen D. J., Runne M. A., Sluiter W. J., de Vries E. G., Willemse P. B., Mulder N. H., van den Berg M. P., Koops H. S., Sleijfer D. T. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18 (8): 1725–1732.

11. Oh J. H., Baum D. D., Pham S. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol. 2007; 24 (2): 175–181.

12. Du X. L., Xia R., Burau K., Liu C. C. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol. 2011; 28: 80–90. DOI 10.1007/s12032–010–9717–7.

13. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med. 2001; 344: 783–792.

14. Piccart-Gebhart M. J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C. H., Steger G., Huang C. S., Andersson M., Inbar M., Lichinitser M., Láng I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T. M., Rüschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M. S., Gelber R.D; Herceptin Adjuvant (HERA) Trial Study Team. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2‑posi- tive breast cancer. N Engl J Med. 2005; 353: 1659–1672.

15. Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E. Jr, Davidson N. E., Tan-Chiu E., Martino S., Paik S., Kaufman P. A., Swain S. M., Pisansky T. M., Fehrenbacher L., Kutteh L. A., Vogel V. G., Visscher D. W., Yothers G., Jenkins R. B., Brown A. M., Dakhil S. R., Mamounas E. P., Lingle W. L., Klein P. M., Ingle J. N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2‑positive breast cancer. N Engl J Med. 2005; 353: 1673–1684.

16. Tan-Chiu E., Yothers G., Romond E., Geyer C. E. Jr, Ewer M., Keefe D., Shannon R. P., Swain S. M., Brown A., Fehrenbacher L., Vogel V. G., Seay T. E., Rastogi P., Mamounas E. P., Wolmark N., Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2‑over- expressing breast cancer: NSABP B31. J Clin Oncol. 2005; 23: 7811–7819.

17. Perez E. A., Suman V. J., Davidson N. E., Sledge G. W., Kaufman P. A., Hudis C. A., Martino S., Gralow J. R., Dakhil S. R., Ingle J. N., Winer E. P., Gelmon K. A., Gersh B. J., Jaffe A. S., Rodeheffer R. J. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by Paclitaxel with or without Trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231–1238.

18. Procter M., Suter T. M., de Azambuja E., Dafni U., van Dooren V., Muehlbauer S., Climent M. A., Rechberger E., Liu W. T., Toi M., Coombes R. C., Dodwell D., Pagani O., Madrid J., Hall M., Chen S. C., Focan C., Muschol M., van Veldhuisen D. J., Piccart-Gebhart M. J. Longer-term assessment of trastuzumab-related cardiac adverse events in the Her- ceptin Adjuvant (HERA) trial. J Clin Oncol. 2010; 28: 3422–3428.

19. Baselga J., Cortés J., Kim S. B., Im S. A., Hegg R., Im Y. H., Roman L., Pedrini J. L., Pienkowski T., Knott A., Clark E., Benyunes M. C., Ross G., Swain S. M.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011; 366 (2): 109–119.

20. Swain S. M., Kim S. B., Cortés J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J. M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2‑positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14 (6): 461–471. doi: 10.1016/S1470–2045 (13)70130‑X.

21. Wolff A. C., Wang M., Li H., Pins M. R., Pretorius F. J., Rowland K. M., Sparano J. A., Davidson N. E. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat. 2010; 121: 111–120.

22. Chia S., Clemons M., Martin L. A., Rodgers A., Gelmon K., Pond G. R., Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER‑2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006; 24: 2773–2778.

23. Andreopoulou E., Gaiotti D., Kim E., Volm M., Oratz R., Freedberg R., Downey A., Vogel C. L., Chia S., Muggia F. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2‑overexpressing metastatic breast cancer. Clin Breast Cancer. 2007; 7: 690–696.

24. Stickeler E., Klar M., Watermann D., Geibel A., Földi M., Hasenburg A., Gitsch G. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat. 2009; 117 (3): 591–598. doi: 10.1007/s10549–008–0306–9.

25. Christodoulou C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., Gogas H., Razis E., Skarlos D. V., Fountzilas G.; Study of the Hellenic Cooperative Oncology Group. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer: phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009; 76: 275–285.

26. O’Brien M. E.., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D. G., Tomczak P., Ackland S. P., Orlandi F., Mellars L., Alland L., Tendler C.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15 (3): 440–449.

27. Perez E. A., Koehler M., Byrne J., Preston A. J., Rappold E., Ewer M. S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proc. 2008; 83 (6): 679–686.

28. Pircher M., Mlineritsch B., Fridrik M. A., Dittrich C., Lang A., Petru E., Weltermann A., Thaler J., Hufnagl C., Gampenrieder S. P., Rinnerthaler G., Ressler S., Ulmer H., Greil R. Lapatinib-plus-pegylated liposomal doxorubicin in advanced her2‑positive breast cancer following trastuzumab: a phase ii trial. Anticancer Res. 2015; 35 (1): 517–522.

29. Yeh ET., Tong A. T., Lenihan D. J., Yusuf S. W., Swafford J., Champion C., Durand J. B., Gibbs H., Zafarmand A. A., Ewer M. S. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109: 3122–3131.

30. Felker G. M., Thompson R. E., Hare J. M., Hruban R. H., Clemetson D. E., Howard D. L., Baughman K. L., Kasper E. K. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342: 1077–1084.

31. Chen M., Colan S., Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011; 108: 619–628.

32. Sawyer D., Lenihan D. Managing heart failure in cancer patients. In: Mann D., Felker G. Heart Failure: A Companion to Braunwald’s Heart Disease, 3d ed. Philadelphia, Elsevier. 2016.

33. Tan-Chiu E., Yothers G., Romond E., Geyer C. E. Jr, Ewer M., Keefe D., Shannon R. P., Swain S. M., Brown A., Fehrenbacher L., Vogel V. G., Seay T. E., Rastogi P., Mamounas E. P., Wolmark N., Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2‑overexpressing breast cancer: NSABP B‑31. J Clin Oncol. 2005; 23: 7811–7819.

34. Swain S., Whaley F., Ewer M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869–2879.

35. Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F. A., Foster E., Goldstein S. A., Kuznetsova T., Lancellotti P., Muraru D., Picard M. H., Rietzschel E. R., Rudski L., Spencer K. T., Tsang W., Voigt J. U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1–39.

36. Plana J. C., Galderisi M., Barac A., Ewer M. S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I. A., Agler D. A., Badano L. P., Banchs J., Cardinale D., Carver J., Cerqueira M., DeCara J. M., Edvardsen T., Flamm S. D., Force T., Griffin B. P., Jerusalem G., Liu J. E., Magalhães A., Marwick T., Sanchez L. Y., Sicari R., Villarraga H. R., Lancellotti P. Expert consensus for multimodality imaging evaluation of adult cancer patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27: 911–939.

37. van Dalen E. C., Caron H. N., Dickinson H. O., Kremer L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011; 6: CD003917. doi:10.1002/14651858.CD003917.pub4.

38. Orditura M.., Quaglia F., Morgillo F., Martinelli E., Lieto E., De Rosa G., Comunale D., Diadema M. R., Ciardiello F., Catalano G., De Vita F. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncology reports. 2004; 12: 549–556.

39. O’Shaughnessy J. Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer. Clin Breast Cancer. 2003; 4: 318–328.

40. O’Brien M. E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D. G., Tomczak P., Ackland S. P., Orlandi F., Mellars L., Alland L., Tendler C.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15: 440–449.

41. Cardinale D., Colombo A., Sandri M. T., Lamantia G., Colombo N., Civelli M., Martinelli G., Veglia F., Fiorentini C., Cipolla C. M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114: 2474–2481.

42. Kalay N.., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan A., Inanc T., Oguzhan A., Eryol N. K., Topsakal R., Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48: 2258–2262.

43. Georgakopoulos P., Roussou P., Matsakas E., Karavidas A., Anagnostopoulos N., Marinakis T., Galanopoulos A., Georgiakodis F., Zimeras S., Kyriakidis M., Ahimastos A. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36‑month follow-up. Am J Hematol. 2010; 85: 894–896.

44. Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., Rubino M., Veglia F., Fiorentini C., Cipolla C. M. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55: 213–220.

45. Lipshultz S. E.., Lipsitz S. R., Sallan S. E., Simbre V. C. 2nd, Shaikh S. L., Mone S. M., Gelber R. D., Colan S. D. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002; 20: 4517–4522.

46. Tallaj J. A., Franco V., Rayburn B. K., Pinderski L., Benza R. L., Pamboukian S., Foley B., Bourge R. C. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005; 24: 2196–2201.

47. Jensen B., Skovsgaard T., Nielsen S. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13: 699–709.


Дополнительные файлы

Для цитирования: Болотина Л.В., Овчинников А.Г. ПРОБЛЕМЫ СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ, ИНДУЦИРОВАННЫХ ХИМИОТЕРАПИЕЙ И ТАРГЕТНЫМИ ПРЕПАРАТАМИ. Исследования и практика в медицине. 2015;2(4):106-114. https://doi.org/10.17709/2409-2231-2015-2-77

For citation: Bolotina L.V., Ovchinnikov A.G. CARDIOVASCULAR COMPLICATIONS CAUSED BY CHEMOTHERAPY AND TARGETED AGENTS. Research'n Practical Medicine Journal. 2015;2(4):106-114. (In Russ.) https://doi.org/10.17709/2409-2231-2015-2-77

Просмотров: 374

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN: 2409-2231 (Print)
ISSN: 2410-1893 (Online)